Last reviewed · How we verify
Vaccine Support Cp (Vaccine Candidate #5)
Vaccine Candidate #5, developed by Pfizer, is a marketed drug with a mechanism of action that provides relief from symptoms of runny nose, fever, and cough. It has undergone 100 trials and has generated $63.6B in revenue. The drug's key indications include relief of symptoms of runny nose, fever, and cough. Vaccine Candidate #5 has no publications associated with it. Its commercial significance lies in its ability to provide relief from common cold symptoms. The drug's pipeline developments are not specified. Overall, Vaccine Candidate #5 is a notable addition to Pfizer's portfolio.
At a glance
| Generic name | Vaccine Candidate #5 |
|---|---|
| Sponsor | Pfizer |
| Drug class | vaccine |
| Target | common cold virus |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Relief of symptoms of runny nose
- Relief of symptoms of fever
- Relief of symptoms of cough
Common side effects
Drug interactions
- Aspirin
- Warfarin
- Ibuprofen
- Clopidogrel
- Pain relievers
- Anticoagulants
- Antiplatelets
- Blood thinners
Key clinical trials
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
- A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus. (PHASE1)
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21 (PHASE1)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) (PHASE1)
- A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaccine Support Cp CI brief — competitive landscape report
- Vaccine Support Cp updates RSS · CI watch RSS
- Pfizer portfolio CI